Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2009

01-10-2009 | Original Article

Six-year dialysis freedom in end-stage renal disease

Author: Aamir Jalal Al Mosawi

Published in: Clinical and Experimental Nephrology | Issue 5/2009

Login to get access

Abstract

Background

Patients with end-stage renal disease (ESRD) cannot sustain life in the absence of renal replacement therapy (RRT). However, a 4-year dialysis freedom with improved well-being has been reported in ESRD using a new therapeutic approach combining conservative measures and acacia gum (AG) supplementation. The aim of this paper is to report the achievement of 6-year dialysis freedom.

Patients and methods

During December 2001, six patients with ESRD and significant uremia that required at least one dialysis session to maintain life were enrolled in a clinical trial investigating the use of a new therapeutic approach combining conservative measures and AG supplementation aiming at improving well-being and providing patients with ESRD dialysis freedom. Three patients were treated with this approach. One patient complied with protocol for only 10 days and died after 6 months peritoneal dialysis. Two patients completed 1 year on this therapeutic regimen. Both patients reported improved well-being. Neither became acidotic nor uremic, and neither required dialysis during the 1 year of the study period. Both patients maintained serum creatinine and urea levels not previously achieved without dialysis. The other three patients were managed with intermittent peritoneal dialysis (IPD). All died within less than 6 months. Of the two surviving patients on AG supplementation, one patient stopped AG supplementation after 1 year and died within 1 month despite IPD. The other patient continued to be treated with this novel approach and continued to experience improved well-being and dialysis freedom. The aim of this paper is to report the achievement of 6-year dialysis freedom in this patient.

Results

During 6 years of therapy the girl continued in experiencing improved well-being and good participation in outdoor activities. Mild uremic symptoms occurred only during periods of noncompliance. Periods of decreased compliance with pharmacologic therapies were associated with anemia and renal osteodystrophy and some degree genue vulgum has resulted.

Conclusion

It was possible to address ESRD in this particular patient as a disease process that can be treated by totally different medical treatment approaches without the use of either chronic dialysis or transplant.
Literature
1.
go back to reference Chugh KS, Jha V. Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int Suppl. 1995;50:S7–13.PubMed Chugh KS, Jha V. Differences in the care of ESRD patients worldwide: required resources and future outlook. Kidney Int Suppl. 1995;50:S7–13.PubMed
2.
go back to reference Jha V. End-stage renal care in developing countries: the India experience. Ren Fail. 2004;26:201–8.CrossRefPubMed Jha V. End-stage renal care in developing countries: the India experience. Ren Fail. 2004;26:201–8.CrossRefPubMed
3.
go back to reference Agodoa LYC, Eggers PW. Renal replacement therapy in the United States: data from the United States Renal Data System. Am J Kidney Dis. 1995;25:119.CrossRefPubMed Agodoa LYC, Eggers PW. Renal replacement therapy in the United States: data from the United States Renal Data System. Am J Kidney Dis. 1995;25:119.CrossRefPubMed
4.
go back to reference Ifudu O, Paul H, Mayers JD, et al. Pervasive failed rehabilitation center-based hemodialysis patients. Am J Kidney Dis. 1994;23:394.CrossRefPubMed Ifudu O, Paul H, Mayers JD, et al. Pervasive failed rehabilitation center-based hemodialysis patients. Am J Kidney Dis. 1994;23:394.CrossRefPubMed
5.
go back to reference Evans RW. Quality of life assessment and the treatment of end-stage renal disease. Transplant Rev. 1990;4:28.CrossRef Evans RW. Quality of life assessment and the treatment of end-stage renal disease. Transplant Rev. 1990;4:28.CrossRef
6.
go back to reference Harper AM, Rosendale JD. The UNOS OPTN waiting list and donor registry: 1988–1996. Harper AM, Rosendale JD. The UNOS OPTN waiting list and donor registry: 1988–1996.
7.
go back to reference Salonen T, Reina T, Oksa H, Sintonen H, Pasternack A. Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis. 2003;42(6):1228–38.CrossRefPubMed Salonen T, Reina T, Oksa H, Sintonen H, Pasternack A. Cost analysis of renal replacement therapies in Finland. Am J Kidney Dis. 2003;42(6):1228–38.CrossRefPubMed
8.
9.
go back to reference Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney Int Suppl. 2003;83:S115–8.CrossRef Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney Int Suppl. 2003;83:S115–8.CrossRef
10.
go back to reference Al-Mosawi AJ. Acacia gum supplementation of a low-protein diet in children with end-stage renal disease. Pediatr Nephrol. 2004;19:1156–9.CrossRefPubMed Al-Mosawi AJ. Acacia gum supplementation of a low-protein diet in children with end-stage renal disease. Pediatr Nephrol. 2004;19:1156–9.CrossRefPubMed
11.
go back to reference Al Mosawi AJ. Continuous renal replacement in the developing world: is there any alternative. Therapy. 2006;3:265–72.CrossRef Al Mosawi AJ. Continuous renal replacement in the developing world: is there any alternative. Therapy. 2006;3:265–72.CrossRef
12.
go back to reference Al-Mosawi AJ. Acacia gum therapeutic potential: possible role in the management of uremia—a new potential medicine. Therapy. 2006;3:301–32.CrossRef Al-Mosawi AJ. Acacia gum therapeutic potential: possible role in the management of uremia—a new potential medicine. Therapy. 2006;3:301–32.CrossRef
13.
go back to reference Chesney RW, Patters A. Acacia gum in chronic renal failure. Therapy. 2006;3:183–5.CrossRef Chesney RW, Patters A. Acacia gum in chronic renal failure. Therapy. 2006;3:183–5.CrossRef
14.
15.
go back to reference Zawad ET Jr. Indications for dialysis. In: Daugirdas JT, Ing TS, editors. Handbook of dialysis. Boston: Little Brown; 1988. p. 3–7. Zawad ET Jr. Indications for dialysis. In: Daugirdas JT, Ing TS, editors. Handbook of dialysis. Boston: Little Brown; 1988. p. 3–7.
16.
go back to reference Briker NS. The pathogenesis of the uremic state: the trade-off hypothesis. N Engl J Med. 1972;286:1093–9.CrossRef Briker NS. The pathogenesis of the uremic state: the trade-off hypothesis. N Engl J Med. 1972;286:1093–9.CrossRef
17.
go back to reference Shoeneman M. Dietary and pharmacologic treatment of chronic renal failure. In: Edelmann CM, editor. Pediatric kidney disease. Boston: Little Brown;1978. p. 475–87. Shoeneman M. Dietary and pharmacologic treatment of chronic renal failure. In: Edelmann CM, editor. Pediatric kidney disease. Boston: Little Brown;1978. p. 475–87.
18.
go back to reference Harmon WE. Chronic renal failure, overview of chronic renal failure. In: Barrat TM, Avner ED, Harmon WE, editors. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 1999. p. 1151–4. Harmon WE. Chronic renal failure, overview of chronic renal failure. In: Barrat TM, Avner ED, Harmon WE, editors. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 1999. p. 1151–4.
19.
go back to reference Schott H, Martin AN. Colloidal and surface—chemical aspects of dosage forms. In: Dettert LW, editor. Sprowl’s American pharmacy an introduction to pharmaceutical techniques and dosage forms. 7th ed. Philadelphia: JB Lippincott Company; 1974. p. 103–47. Schott H, Martin AN. Colloidal and surface—chemical aspects of dosage forms. In: Dettert LW, editor. Sprowl’s American pharmacy an introduction to pharmaceutical techniques and dosage forms. 7th ed. Philadelphia: JB Lippincott Company; 1974. p. 103–47.
20.
go back to reference US Food and Drug Administration GRAS (generally recommended as safe) food ingredient gum arabic. US Department of Commerce: Washington; 1972. (NT/Sno PB 223-614). US Food and Drug Administration GRAS (generally recommended as safe) food ingredient gum arabic. US Department of Commerce: Washington; 1972. (NT/Sno PB 223-614).
21.
go back to reference Philips GO. Acacia gum (gum arabic): a nutritional fiber metabolism and caloric value. Food Addit Contam. 1988;15:251–64.CrossRef Philips GO. Acacia gum (gum arabic): a nutritional fiber metabolism and caloric value. Food Addit Contam. 1988;15:251–64.CrossRef
22.
go back to reference Harley LJ, Davis IR, Livesey G. Digestible energy value of gums in rats-data on gum arabic. Food Addit Contam. 1989;6:13–20.CrossRefPubMed Harley LJ, Davis IR, Livesey G. Digestible energy value of gums in rats-data on gum arabic. Food Addit Contam. 1989;6:13–20.CrossRefPubMed
23.
go back to reference Ross AH, Eastwood MA, Brydon WG, Anderson GR, Anderson. DM. A study of the effects of dietary gum arabic in humans. Am J Clin Nutr. 1983;37(3):368–75.CrossRefPubMed Ross AH, Eastwood MA, Brydon WG, Anderson GR, Anderson. DM. A study of the effects of dietary gum arabic in humans. Am J Clin Nutr. 1983;37(3):368–75.CrossRefPubMed
24.
go back to reference Anderson DM, Ashby P, Busuttil A, Eastwood MA, et al. Subchronic effect of gum arabic (acacia) in rats. Toxicol Lett. 1982;14:221–7.CrossRefPubMed Anderson DM, Ashby P, Busuttil A, Eastwood MA, et al. Subchronic effect of gum arabic (acacia) in rats. Toxicol Lett. 1982;14:221–7.CrossRefPubMed
25.
go back to reference Collins TF, Welsh JJ, Black TN, Graham SL, Brown LH. Study of the teratogenic potential of gum arabic. Food Chem Toxicol. 1987;25:815–21.CrossRefPubMed Collins TF, Welsh JJ, Black TN, Graham SL, Brown LH. Study of the teratogenic potential of gum arabic. Food Chem Toxicol. 1987;25:815–21.CrossRefPubMed
26.
go back to reference Melnick RL, Huff J, Haseman JK, Dieter MP, Grieshaber CK, Wyand DS, et al. Chronic effects of agar, guar gum, gum arabic, locust-bean gum, or tara gum in F344 rats and B6C3F1 mice. Food Chem Toxicol. 1983;21:305–11.CrossRefPubMed Melnick RL, Huff J, Haseman JK, Dieter MP, Grieshaber CK, Wyand DS, et al. Chronic effects of agar, guar gum, gum arabic, locust-bean gum, or tara gum in F344 rats and B6C3F1 mice. Food Chem Toxicol. 1983;21:305–11.CrossRefPubMed
27.
go back to reference National Toxicology Programme. Carcinogenesis Bioassay of Gum Arabic (CAS no.9000-01-5) in F344 Rats and B6C3F1 Mice (feed study). National Toxicology Program Technical Report Series 1982; 227:1–124. National Toxicology Programme. Carcinogenesis Bioassay of Gum Arabic (CAS no.9000-01-5) in F344 Rats and B6C3F1 Mice (feed study). National Toxicology Program Technical Report Series 1982; 227:1–124.
28.
go back to reference Anderson DM. Evidence for the safety of gum arabic (acacia Senegal (L) Wild.) as a food additive—a brief review. Food Addit Contam. 1986;3:225–30.CrossRefPubMed Anderson DM. Evidence for the safety of gum arabic (acacia Senegal (L) Wild.) as a food additive—a brief review. Food Addit Contam. 1986;3:225–30.CrossRefPubMed
29.
go back to reference Bliss DZ. Potential therapeutic benefits of dietary fiber for renal patients. Proceeding of a round table on medical issues: renal nutrition. Columbus: Ross Laboratories; 1991. p. 94–99. Bliss DZ. Potential therapeutic benefits of dietary fiber for renal patients. Proceeding of a round table on medical issues: renal nutrition. Columbus: Ross Laboratories; 1991. p. 94–99.
30.
go back to reference Little P, Trafford A. Dietary and renal failure, comparison of sterculia and ispaghula. Clin Nephrol. 1991;36:309.PubMed Little P, Trafford A. Dietary and renal failure, comparison of sterculia and ispaghula. Clin Nephrol. 1991;36:309.PubMed
31.
go back to reference Bliss DZ, Stein TP, Schleifer CR, Settle RG. Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen excretion in chronic renal failure patients consuming a low protein diet. Am J Clin Nutr. 1996;63:392–8.CrossRefPubMed Bliss DZ, Stein TP, Schleifer CR, Settle RG. Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen excretion in chronic renal failure patients consuming a low protein diet. Am J Clin Nutr. 1996;63:392–8.CrossRefPubMed
32.
go back to reference Yatzidis H, Kousticos D, Digenis P. Oral locust been gum therapy of uremia: favorable effects on biological a abnormalities and hypertension. Dial Transplant. 1980;9:313–7. Yatzidis H, Kousticos D, Digenis P. Oral locust been gum therapy of uremia: favorable effects on biological a abnormalities and hypertension. Dial Transplant. 1980;9:313–7.
33.
go back to reference Vacoe R, Halliday D, Carson ER. Efficiency for utilization of urea nitrogen for albumin synthesis by chronically uremic and normal man. Clin Sci Mol Med. 1975;48:379. Vacoe R, Halliday D, Carson ER. Efficiency for utilization of urea nitrogen for albumin synthesis by chronically uremic and normal man. Clin Sci Mol Med. 1975;48:379.
34.
go back to reference Walser M. Urea metabolism in chronic renal failure. J Clin Invest. 1970;53:1385.CrossRef Walser M. Urea metabolism in chronic renal failure. J Clin Invest. 1970;53:1385.CrossRef
35.
go back to reference Ruman D. Nutrition requirement. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JD, Fauci AS, editors. Harrison’s principles of internal medicine. 11th ed. New York: Mc Graw-Hill;1987. p. 383–9. Ruman D. Nutrition requirement. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JD, Fauci AS, editors. Harrison’s principles of internal medicine. 11th ed. New York: Mc Graw-Hill;1987. p. 383–9.
36.
go back to reference Stephen AM, Cummings JH. Mechanism of action of dietary fiber in the human colon. Nature. 1980;284:283–4.CrossRefPubMed Stephen AM, Cummings JH. Mechanism of action of dietary fiber in the human colon. Nature. 1980;284:283–4.CrossRefPubMed
37.
go back to reference Cummings JH. Dietary fiber and the intestinal micro flora. In: Hallgren B, editor. XV Symposium of Swedish Nutritional Foundation. Stockholm: Almqvist & Wiskell International; 1983. p. 77–87. Cummings JH. Dietary fiber and the intestinal micro flora. In: Hallgren B, editor. XV Symposium of Swedish Nutritional Foundation. Stockholm: Almqvist & Wiskell International; 1983. p. 77–87.
38.
go back to reference Brown CL, Hill MJ, Richards P. Bacterial ureases in uremic men. Lancet. 1971;1:405–7. Brown CL, Hill MJ, Richards P. Bacterial ureases in uremic men. Lancet. 1971;1:405–7.
40.
go back to reference Smith CJ, Bryant MP. Introduction to metabolic activities of intestinal bacteria. Am J Clin Nutr. 1979;32:149–57.CrossRefPubMed Smith CJ, Bryant MP. Introduction to metabolic activities of intestinal bacteria. Am J Clin Nutr. 1979;32:149–57.CrossRefPubMed
41.
go back to reference Wrong OM, Edmonds CJ, Chadwi KVS. The large intestine its role in mammalian nutrition and homeostasis. NY: Wiley; 1981. p. 133–55. Wrong OM, Edmonds CJ, Chadwi KVS. The large intestine its role in mammalian nutrition and homeostasis. NY: Wiley; 1981. p. 133–55.
Metadata
Title
Six-year dialysis freedom in end-stage renal disease
Author
Aamir Jalal Al Mosawi
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0181-7

Other articles of this Issue 5/2009

Clinical and Experimental Nephrology 5/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.